CARGO Therapeutics
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
CARGO Therapeutics developed cell therapies for cancer, including investigational CAR T treatments.
02 / CARGO Therapeutics FAILURE REASONS
Failure reasons
Safety events and insufficient durability of response led the company to judge firi-cel’s benefit-risk profile uncompetitive and discontinue its study. The board later stopped remaining development programs while seeking a business combination.
03 / EVENT HISTORY
Events in the structured record
- Lead study discontinued
On 29 January CARGO stopped FIRCE-1 and announced approximately 50% workforce reductions.
- Remaining development suspended
On 18 March it suspended remaining programs and announced a further approximately 90% workforce reduction.
- Acquisition completed
On 19 August 2025 the merger with Concentra Biosciences was completed.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Lead trial failed management’s benefit-risk expectations
- 02
FIRCE-1 discontinued
- 03
Remaining development suspended while strategic options were pursued